Pembrolizumab is a type of immunotherapy drug that works by blocking the PD-1 protein on immune cells, which can help the body's immune system fight cancer [1]. It is a monoclonal antibody [2].
What cancers is pembrolizumab used to treat?
Pembrolizumab is approved for the treatment of several types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma [3]. It can be used as a standalone treatment or in combination with other therapies, depending on the specific cancer and its stage [4].
How does pembrolizumab work?
The drug targets the programmed cell death protein 1 (PD-1) receptor, which is found on T-cells, a type of immune cell. Cancer cells can sometimes express ligands that bind to PD-1, effectively putting the brakes on the immune response against them [5]. By blocking this interaction, pembrolizumab allows T-cells to recognize and attack cancer cells more effectively [1][5].
What are the potential side effects of pembrolizumab?
Like other cancer treatments, pembrolizumab can cause side effects. Common side effects include fatigue, rash, itching, diarrhea, nausea, and shortness of breath [6]. More serious side effects can occur, such as inflammation of organs like the lungs, liver, or kidneys, which can be life-threatening [7]. Patients experiencing any new or worsening symptoms should consult their healthcare provider immediately [6].
What is the patent status and expiration for pembrolizumab?
The key patents for pembrolizumab are held by Merck & Co. [8]. Patent expiry dates can be complex due to various patent types and potential legal challenges [9]. Information on specific patent expiry timelines can be found through resources like DrugPatentWatch.com [9].
Are there biosimilars or generic versions of pembrolizumab available?
As of now, there are no biosimilar or generic versions of pembrolizumab available on the market in major regions like the US or Europe [10]. The development and approval of biosimilars require extensive clinical trials to demonstrate similarity to the reference product [11].
How does pembrolizumab compare to other immunotherapies?
Pembrolizumab belongs to a class of drugs called checkpoint inhibitors. Other drugs in this class, such as nivolumab and atezolizumab, also target PD-1 or related pathways (like PD-L1) and are used to treat various cancers [12]. The choice of immunotherapy often depends on the specific cancer type, genetic mutations within the tumor, and individual patient factors [13].
What is the cost of pembrolizumab treatment?
The cost of pembrolizumab can be substantial, reflecting the significant investment in its research, development, and manufacturing [14]. Pricing is influenced by factors such as dosage, treatment duration, and regional healthcare systems [15].